Compare FBGL & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | NCEL |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | Singapore | Switzerland |
| Employees | N/A | 11 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.3M |
| IPO Year | N/A | N/A |
| Metric | FBGL | NCEL |
|---|---|---|
| Price | $1.09 | $2.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 47.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.89 |
| 52 Week High | $1.20 | $4.70 |
| Indicator | FBGL | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 47.36 |
| Support Level | $0.53 | $2.44 |
| Resistance Level | $1.14 | $3.19 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.05 | 8.27 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.